PRF Technologies Reports H1 2026 Results: $11.6M Cash, FDA-Cleared OcuRing™-K Phase II, and a Nasdaq MVLS Delisting Risk
PRFX is trading near its 52-week low of $0.912 (9.6% above the low).
Summary
PRF Technologies reported H1 2026 results with $11.6M in cash and an FDA-cleared Phase II for OcuRing™-K, but also disclosed its Nasdaq MVLS is below the $5M threshold under a new delisting rule.
Key Events · Earnings and Guidance · PRFX
-
H1 2026 Net Loss of $2.8M
Net loss attributable to shareholders was $2.8M for H1 2026, up from $2.3M in H1 2025, driven by higher R&D and SEPA-related financing costs.
-
Cash Position Nearly Tripled
Cash, short-term deposits, and restricted cash totaled $11.6M as of June 30, 2026, up from $4.2M at year-end 2025, after raising $10M under the May 2026 SEPA.
-
Nasdaq MVLS Delisting Risk
MVLS was approximately $3.4M as of September 2, 2026, below the $5.0M threshold under a new Nasdaq rule. If the SEC stay is lifted, the company could face immediate suspension and delisting without a cure period.
-
FDA Clears OcuRing™-K IND
FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in H2 2026.
Analysis · PRFX · Life Sciences
PRF Technologies disclosed its first-half 2026 financials alongside a critical Nasdaq listing risk. The company ended June with $11.6 million in cash — nearly triple year-end 2025 — after raising $10 million via a Yorkville SEPA in May. But the filing also reveals that as of September 2, 2026, its Market Value of Listed Securities was approximately $3.4 million, below the $5.0 million threshold under a new Nasdaq rule that, if the SEC stay is lifted, could trigger immediate suspension and delisting without a cure period. That is a thesis-altering risk for a micro-cap already trading at $1.00. Operationally, the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II cataract trial with enrollment expected in H2 2026, and PRF-110 showed 72-hour analgesic activity comparable to an approved benchmark. The balance sheet is stronger, but the listing overhang is the dominant near-term issue.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.91 to $9.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.